Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Large Is the Conjugate Vaccine Market Expected to Be in 2029?

In the past few years, there has been a swift expansion in the size of the conjugate vaccine market. The market is poised to escalate from $18.9 billion in 2024 to $21.26 billion in 2025, reflecting a compound annual growth rate (CAGR) of 12.5%. Factors fueling the growth during the historical period include the burden of diseases, implementation of government immunization programs, heightened awareness, a focus on pediatric vaccination, and preventive healthcare trends.

Over the coming years, the conjugate vaccine market is anticipated to witness swift expansion. The market size is projected to soar to “$33.99 billion in 2029”, boasting a compound annual growth rate (CAGR) of “12.4%”. The surge during this forecasted period can be credited to factors such as broadening immunization policies, an aging demographic, introduction of new vaccine indications, international health security issues, global cooperation, and the effects of economic development. The period also unveils major trends like collaborations and partnerships for distributing vaccines, tailored strategies for high-risk groups, applications in the field of emerging infectious diseases, technological advancements in vaccine production, along with worldwide health initiatives advocating for vaccine equality.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What Are The Contributors To Demand In The Conjugate Vaccine Market?

The conjugate vaccine market is predicted to grow due to the rising use of these vaccines among adults. Conjugate vaccines play a crucial role in provoking a powerful immune response against bacterial capsular polysaccharides, thus enhancing the body’s capacity to ward off bacterial infections. The incorporation of conjugate vaccines into adult immunization schedules helps minimize the risk of severe disease, complications, and transmission of bacterial illnesses by eliciting a strong immune response. For instance, a report from the UK Health Security Agency (UKHSA) in June 2024, indicated that the ‘6-in-1’ vaccine in the UK had a consistent 12-month coverage of 91.7%. The pneumococcal conjugate vaccine (PCV) sustained an uptake of 93.7%. The cover for the Rotavirus saw a rise of 0.6%, touching 89.3%, while the second dose of the meningitis B vaccine (MenB2) increased by 0.1%, reaching 91.5%. These trends indicate that the escalating use of conjugate vaccines for adults is fueling the growth of the conjugate vaccine market.

What Segmentation Categories Are Included In The Conjugate Vaccine Market Analysis?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Long-Term Trends Are Likely To Affect The Conjugate Vaccine Market?

The growing trend of innovation in the field of conjugate vaccines is witnessing significant traction in the conjugate vaccine market. Market players in the conjugate vaccine space are diligently developing novel conjugate vaccines to secure their market position. As an illustration, Pfizer Inc., a biotechnology and pharmaceutical company headquartered in the US, released Prevnar 20, a pneumococcal 20-valent conjugate vaccine in Canada in June 2022. Aimed at preventing pneumonia and formidable pneumococcal infections in adults aged 18 years and up, Prevnar 20 incorporates conjugates for an extra seven serotypes linked to invasive pneumococcal disease, elevated fatality rates in cases, resistance to antibiotics, and meningitis, in addition to the 13 serotypes already covered by PREVNAR 13.

Who Are The Top-Ranked Companies In The Conjugate Vaccine Market Today?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

How Is Conjugate Vaccine Market Adoption Varying Across Different Regions And Sectors?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model